Page 4,896«..1020..4,8954,8964,8974,898..4,9104,920..»

Hyperbaric chamber treatments did not help with mild TBI

Posted: Published on September 21st, 2013

Scientists found no significant benefit to a popular idea of using a pressurized chamber to force oxygen into the brain to heal mild brain injuries suffered by tens of thousands of Iraq and Afghanistan combat veterans, according to a scientific study by the Pentagon and Department of Veterans Affairs published this week. "There's no magic bullet," David Cifu, VA national director for physical medicine and rehabilitation services. "We wished it worked. ... But it didn't work." The study results leave the military and the VA without any tool for directly treating an injury characterized as a "signature wound" of the two wars. Some troops exposed to several roadside bombs during operations had more than one mild traumatic brain injury (TBI) or concussion from exposure to blasts. More than 230,000 troops have suffered mild TBI since 2000, according to the Pentagon. Ten percent of Iraq and Afghanistan veterans at the VA report ongoing mild brain injury symptoms such as headaches, light sensitivity and problem-solving deficits. The hyperbaric chamber thought to be an answer is identical to decompression chambers used to treat divers suffering from the bends or decompression sickness. A group of private doctors contend they have used hyperbaric chambers to … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Hyperbaric chamber treatments did not help with mild TBI

Gum Disease Treatment in Jackson, MS can Now Help Prevent Bone and Tooth Loss using Stimulation from Laser Gum Surgery …

Posted: Published on September 21st, 2013

Jackson, MS (PRWEB) September 21, 2013 Dr. Roger B. Parkes and Dr. R. Clarke Steward are certified to perform the most advanced laser gum disease treatment option in Jackson, which treats gum disease and decreases the risk of tooth and bone loss. The Laser Assisted New Attachment Procedure (LANAP) is the only FDA cleared laser available for the treatment of gum disease. Gum disease begins with harmless-seeming symptoms such as sensitivity of the gums, gums that bleed easily and inflammation. Many sufferers ignore these symptoms, sometimes out of fear of traditional dental procedures, and often because they are unaware of the severity of potential health issues related to gum disease. One of these issues is the deterioration of bone in the jaw. In some cases, the infection associated with gum disease causes the bone in the area to recede away from the tooth, leading to tooth loss. Bone loss occurs rapidly when a tooth is lost, because it is no longer stimulated by the roots of the tooth. Drs. Parkes and Steward believe in helping patients keep their natural teeth whenever possible. LANAP uses a highly specialized laser to kill harmful bacteria in the mouth and to remove damaged tissue. … Continue reading →

Posted in MS Treatment | Comments Off on Gum Disease Treatment in Jackson, MS can Now Help Prevent Bone and Tooth Loss using Stimulation from Laser Gum Surgery …

Harvard launches $US6.5 bn capital bid

Posted: Published on September 21st, 2013

HARVARD University has launched a $US6.5 billion ($A6.92 billion) capital campaign that, if successful, would be the largest fundraising effort in the history of higher education. The school on Saturday said the campaign had broad goals spanning all its schools and would fund research into neuroscience, stem cell science and low-cost energy for the developing world. The campaign will target major renovations of the university's undergraduate housing and increase its study of new learning and teaching strategies. It also aims to expand the school's global presence, including through an ongoing project to develop a centre in Shanghai for conferences and research. Harvard President Drew Gilpin Faust said the campaign will help the school meet the world's increasingly complex needs. "We will meet these challenges, and in doing so, we will reaffirm what makes Harvard - and universities in general - such essential and irreplaceable contributors to the pursuit of knowledge and the welfare," Faust said in a press release. The campaign quietly began two years ago. Harvard says it has already raised $US2.8 billion ($A2.98 billion) in gifts and pledges, some of which has already been used. The school aims to reach its $US6.5 billion goal by 2018. If it … Continue reading →

Posted in Stem Cell Research | Comments Off on Harvard launches $US6.5 bn capital bid

Plastic and Aesthetic surgery in Munich – Video

Posted: Published on September 21st, 2013

Plastic and Aesthetic surgery in Munich Presentation of Dr. Dominik von Lukowicz, Ästhetik in München, Plastic and Aesthetic surgery (in German) By: LUKI-MED … Continue reading →

Posted in Aesthetic Surgery | Comments Off on Plastic and Aesthetic surgery in Munich – Video

CureDuchenne Media Statement re: Phase III Clinical Trial Results for Drisapersen, GlaxoSmithKline/Prosensa …

Posted: Published on September 21st, 2013

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--While we are disappointed by the Phase III trial results for drisapersen, we hold out hope that they will provide critical information to the research community that can be applied in future studies, including those by GlaxoSmithKline and Prosensa, said Debra Miller, CEO and Founder, CureDuchenne. We are fully confident in the exon skipping technology as a viable platform to develop a treatment for Duchenne, and Duchenne families should not give up hope. We are fully confident in the exon skipping technology as a viable platform to develop a treatment for Duchenne, and Duchenne families should not give up hope. In addition to its support of Glaxo and Prosensa, CureDuchenne is working with multiple companies to develop a robust pipeline of potential drugs to treat Duchenne. CureDuchenne also provided early support to Sarepta, another company in trials for its exon skipping drug, eteplirsen. Currently, there is no treatment for Duchenne, a progressive muscle-wasting disease and the most common and lethal form of muscular dystrophy. Duchenne impacts one in every 3,500 boys; nearly 20,000 boys are living with the disease in the United States. Boys with Duchenne are usually diagnosed before the age of 5 and are in … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on CureDuchenne Media Statement re: Phase III Clinical Trial Results for Drisapersen, GlaxoSmithKline/Prosensa …

GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne …

Posted: Published on September 21st, 2013

LONDON and LEIDEN, Netherlands, Sept. 20, 2013 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Prosensa today announced that GSK's Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance (6MWD) test compared to placebo. A total of 186 boys were randomised to this double-blind, placebo-controlled study (DMD114044) and received drisapersen at a dose of 6mg/kg/week (N=125) or placebo (N=61) via subcutaneous injection over 48 weeks. The difference in 6MWD (mean (CI) 10.33m (-14.65, 35.31), p=0.415) between drisapersen and placebo groups did not reach statistical significance. There was no treatment difference in key secondary assessments of motor function: 10-meter walk/run test, 4-stair climb and North Star Ambulatory Assessment. The most commonly reported adverse events included injection site reactions (78% for drisapersen vs 16% for placebo) and renal adverse events (including subclinical proteinuria; 46% for drisapersen vs 25% for placebo). No patients had thrombocytopenia. Full evaluation of the benefit-to-risk profile of drisapersen treatment across all studies is anticipated to be completed by year end. This may include analyses of pooled results from various … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on GSK and Prosensa Announce Primary Endpoint Not Met in Phase III Study of Drisapersen in Patients With Duchenne …

Prosensa Sinks as Muscular Dystrophy Drug Fails in Trial

Posted: Published on September 21st, 2013

Prosensa Holding NV (RNA) plunged 70 percent after the Dutch companys experimental muscular dystrophy drug failed to help patients walk better in a clinical trial. Sarepta Therapeutics Inc. (SRPT), the maker of another experimental medicine for the disease, soared. Prosensa dropped to $7.14 at the close in New York, with trading volume 87 times the three-month daily average. The Leiden, Netherlands-based companys shares are listed on the Nasdaq Stock Market. Sarepta, based in Bothell, Washington, jumped 18 percent to $43.30 for the biggest gain in more than 10 months. Prosensa is developing the treatment, drisapersen, with London-based GlaxoSmithKline Plc. (GSK) In a late-stage study dubbed Demand III, drisapersen failed to help patients more than a placebo in a test of six-minute walking distance, the companies said today in a statement. The results call into question the future of the drug, as the partners said they will conduct a full evaluation of the benefit-to-risk profile across all studies that will be completed by the end of 2013. While we are disappointed that this study did not meet its primary endpoint, we remain committed to the overall program and will continue to work closely with GSK, Prosensa Chief Executive Officer Hans Schikan … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Prosensa Sinks as Muscular Dystrophy Drug Fails in Trial

GlaxoSmithKline drug fails in late-stage trial

Posted: Published on September 21st, 2013

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on GlaxoSmithKline drug fails in late-stage trial

Muscular dystrophy drug fails in GSK study, Prosensa slumps

Posted: Published on September 21st, 2013

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Muscular dystrophy drug fails in GSK study, Prosensa slumps

New Data for Zonegran® (Zonisamide), Fycompa® (Perampanel) and Zebinix® (Eslicarbazepine Acetate) to be Presented at …

Posted: Published on September 21st, 2013

New data from three abstracts on Eisai's epilepsy portfolio are to be presented at this year's World Congress of Neurology (WCN) in Vienna. The abstracts include a long-term safety and efficacy clinical study of Zonegran (zonisamide) monotherapy,[1] and two real-life safety and efficacy studies of Fycompa (perampanel)[2] and Zebinix (eslicarbazepine acetate).[3][*] The first abstract to be presented at the WCN on Sunday 22 September shows that zonisamide monotherapy demonstrated favourable long-term safety and maintenance of efficacy in the study group (n=295), with no new or unexpected safety findings.[1] This double-blind, extension study looked at the long-term safety and maintenance of efficacy of zonisamide versus carbamazepine monotherapy for partial seizures in adults with newly diagnosed epilepsy. The incidence of treatment-emergent adverse events (TEAEs) was similar for both zonisamide and carbamazepine (52.6% vs. 46.2%) as was the proportion of patients remaining seizure free for over 24 months (32.3% vs. 35.2%, intent to treat population).[1] Zonisamide is an anti-epileptic drug (AED) with multiple mechanisms of action and a structure which is chemically unrelated to any other AED.[4] In July 2012, zonisamide received EMA approval as monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy.[4] … Continue reading →

Comments Off on New Data for Zonegran® (Zonisamide), Fycompa® (Perampanel) and Zebinix® (Eslicarbazepine Acetate) to be Presented at …

Page 4,896«..1020..4,8954,8964,8974,898..4,9104,920..»